BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311

Reuters

Oct 06

Oct 6 (Reuters) - Invivyd Inc IVVD.O:

INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID
INVIVYD INC: DECLARATION AND LIBERTY CLINICAL TRIALS EXPECTED TO BEGIN AROUND YEAR-END 2025; TOP-LINE DATA ANTICIPATED MID-2026
INVIVYD INC - PLANS TRIAL START BY YEAR-END 2025, TOP-LINE DATA MID-2026

Source text: ID:nGNX1mjbc9

Further company coverage: IVVD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573758679"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573758679\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573758679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573758679","market":"nz","top_or_hot":-1,"title":"BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Invivyd Inc <span>IVVD.O</span>:</p><ul><li><p>INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID</p></li><li><p>INVIVYD INC:  DECLARATION AND LIBERTY CLINICAL TRIALS EXPECTED TO BEGIN AROUND YEAR-END 2025; TOP-LINE DATA ANTICIPATED MID-2026</p></li><li><p>INVIVYD INC - PLANS TRIAL START BY YEAR-END 2025, TOP-LINE DATA MID-2026</p></li></ul><p>Source text: <span>ID:nGNX1mjbc9</span></p><p>Further company coverage: <span>IVVD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 19:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Invivyd Inc <span>IVVD.O</span>:</p><ul><li><p>INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID</p></li><li><p>INVIVYD INC:  DECLARATION AND LIBERTY CLINICAL TRIALS EXPECTED TO BEGIN AROUND YEAR-END 2025; TOP-LINE DATA ANTICIPATED MID-2026</p></li><li><p>INVIVYD INC - PLANS TRIAL START BY YEAR-END 2025, TOP-LINE DATA MID-2026</p></li></ul><p>Source text: <span>ID:nGNX1mjbc9</span></p><p>Further company coverage: <span>IVVD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVVD","symbol_name":"Invivyd, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA3SHNQM:1","article_id":"2573758679","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573758679","pubTimestamp":1759749192,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311Oct 6 (Reuters) - Invivyd Inc IVVD.O:INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVVD":"Invivyd, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"简介-Invivyd获得FDA批准开始新冠阻断抗体VYD2311的关键试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9},"content_text":"BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311Oct 6 (Reuters) - Invivyd Inc IVVD.O:INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVIDINVIVYD INC:  DECLARATION AND LIBERTY CLINICAL TRIALS EXPECTED TO BEGIN AROUND YEAR-END 2025; TOP-LINE DATA ANTICIPATED MID-2026INVIVYD INC - PLANS TRIAL START BY YEAR-END 2025, TOP-LINE DATA MID-2026Source text: ID:nGNX1mjbc9Further company coverage: IVVD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}